Non-Hodgkin Lymphoma (NHL)

Epcoritamab added to R2 sharply boosts follicular lymphoma responses, but infection risks and real-world feasibility raise tough treatment decisions.

As CAR T-cell therapy reaches community oncology, practice leaders discuss the challenges of payer hurdles, single case agreements, apheresis costs and whether to pursue accreditation.

Off-the-shelf cema-cel clears MRD at more than triple the rate of observation alone—and may propel a shift to frontline use of CAR T-cell therapy when relapse is hard to detect.

Ultrasound AI models use radiomics and deep learning to predict DLBCL survival, enabling low-cost, noninvasive risk stratification.

The FDA now permits outpatient monitoring for epcoritamab’s first full dose in R/R DLBCL, as EPCORE-NHL-6 data support safe bispecific antibody access.

Interim data from the EPCORE-NHL-6 trial show safety outcomes similar to those in the pivotal trial that led to approval for the bispecific T-cell–engaging antibody.

DLBCL is the most common subtype of non-Hodgkin lymphoma, known for its aggressiveness and heterogeneity. This presents treatment challenges if patients relapse following the initial chemoimmunotherapy regimen.

The results are the latest from the multiarm EPCORE-NHL-2 trial, which has studied the bispecific antibody epcoritamab in multiple uses and combinations.

Genmab’s epcoritamab (Epkinly) streamlines bispecific antibody workflows for DLBCL and follicular lymphoma, cutting chair time, waste, and costs.

Epcoritamab delivers lasting 3-year remissions in relapsed large B-cell lymphoma, with over half of complete responders staying progression-free.

MicroRNAs are central regulators of DLBCL biology and show strong potential as minimally invasive biomarkers to improve disease classification, prognosis, and treatment personalization.

The need for at-home caregivers in cancer care is not new. But as therapies improve, the need to care for patients with cancer stretches over longer periods. Today, the rise of advanced cellular therapies asks more of caregivers. First in a multipart series that will examine how the healthcare landscape relies on unpaid caregiving, and how alternatives are needed.

Dexamethasone pretreatment significantly reduces GI complications in DLBCL patients undergoing R-CHOP, maintaining efficacy and improving safety.

Allo-CAR-NK cell therapy shows promise in achieving long-term remission for patients with Waldenström lymphoma without chemotherapy.

The Chief Medical Officer of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and safety in non-Hodgkin lymphoma treatment. This exchange appears in the January issue of Evidence-Based Oncology, the annual recap of the meeting of the American Society of Hematology.

In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable toxicity in older, chemotherapy-ineligible patients with LBCL.

Patients with DLBCL who were treated with R-CHOP and quickly relapsed or were refractory to therapy had poor outcomes on second-line therapy.

Advancements in 2025 in non-Hodgkin lymphoma treatments focused on bringing CAR T-cell therapy and bispecific antibodies into the community setting.

A small set of pre-apheresis biological factors can reliably predict whether patients with DLBCL will achieve the T cell collection efficiency needed for successful CAR T manufacturing

In real-world usage, 97% of cases of cytokine release syndrome following treatment with lisocabtagene maraleucel happened within 15 days of infusion.

Chimeric antigen receptor T-cell therapies, along with bispecific antibodies, have changed the treatment paradigm for patients with relapsed or refractory mantle cell lymphoma.

The FDA approved epcoritamab with rituximab and lenalidomide for relapsed follicular lymphoma, offering a promising fixed-duration treatment option for patients after their first relapse.

Routine flow cytometry can reliably track chimeric antigen receptor (CAR) T-cell expansion and persistence in aggressive large B-cell lymphoma (LBCL).

The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS, in relapsed/refractory LBCL.

New reporting suggests obesity and diffuse large B-cell lymphoma (DLBCL) have shared genetic risk factors.